RedWhite Umbrella Consulting LLP.

is a specialized consulting company, active in the international financial, medical and pharmaceutical field. Established in 2012, based in London, United Kingdom.


In accordance with our strategic partnership with Oncotherm, our company provides International Business Development services in many countries and regions. Currently, our cooperation extends for Spain, Portugal, France, Countries of the Gulf Cooperation Council (GCC), Maghreb region and South America (Argentina, Chile, Colombia, Ecuador, Peru)  and our goal is to expand our services to further territories in Asia and South America.

read more

OUr services

financial services

Our company has a strategic partnership with one of the leading alternative Corporate Investment Banking & Asset Management Non-Bank Financial Institutions. Through our partner we offer sophisticated financial services to companies, governments, institutions, and individuals, advising on corporate strategy and structure; raising equity and debt capital; managing complex investment portfolios; and providing access to developed and emerging financial markets. Our company conducts these services with the highest degree of confidentiality and has a privacy statement in order to demonstrate our company commitment to information security, loyalty, ethics and corporate governance and Client confidentiality.


Our services in Pharmaceutical Industry cover what a clinical research organization (CRO) does usually provide and a little bit more. We are able to manage clinical trials for pharmaceutical, medical device, and biotechnology companies, including feasibility studies, selecting the best sites, obtaining the Health Authority approvals, providing necessarry equipment for conducting the study, organizing patient home-visit services, supporting the patient recruitment, validating the collected data, analyzing the statistics, writing study reports, and during these activities we are maintaining advantageous partnerships with Sponsor companies that have promising and valuable drug candidate pipelines.